MARX Biotech Co (ROCO:7731) ROC (Joel Greenblatt) %: 60.43% (As of Dec. 2025) — 398% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7731 MARX Biotech Co Ltd ROCO:7731
6 GF Score
Price NT$4.70
! 5 Warning Signs
View Full Analysis

What is MARX Biotech Co ROC (Joel Greenblatt) %?

MARX Biotech Co ROCO:7731 -5.05% 6 ROC (Joel Greenblatt) % is 60.43% as of Dec. 2025, which is 398% above its 10-year median of 12.14. GuruFocus rates ROCO:7731 with a GF Score™ of 6/100. The stock has 5 warning signs investors should review. Among 669 Healthcare Providers & Services companies, MARX Biotech Co ranks better than 62.18% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. MARX Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 60.43%.

The historical rank and industry rank for MARX Biotech Co's ROC (Joel Greenblatt) % or its related term are showing as below:

ROCO:7731' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -43.95   Med: 12.14   Max: 39.68
Current: 20.74

During the past 6 years, MARX Biotech Co's highest ROC (Joel Greenblatt) % was 39.68%. The lowest was -43.95%. And the median was 12.14%.

ROCO:7731's ROC (Joel Greenblatt) % is ranked better than
62.18% of 669 companies
in the Healthcare Providers & Services industry
Industry Median: 12.54 vs ROCO:7731: 20.74

MARX Biotech Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


MARX Biotech Co  (ROCO:7731) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


MARX Biotech Co ROC (Joel Greenblatt) % Related Terms


MARX Biotech Co ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for MARX Biotech Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MARX Biotech Co ROC (Joel Greenblatt) % Chart

MARX Biotech Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial 39.68 12.14 -23.24 -43.95 24.15

MARX Biotech Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.05 -106.02 -40.18 -16.94 60.43

MARX Biotech Co ROC (Joel Greenblatt) % Competitor Comparison

For the Pharmaceutical Retailers subindustry, MARX Biotech Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MARX Biotech Co ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MARX Biotech Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where MARX Biotech Co's ROC (Joel Greenblatt) % falls into.


ROCO:7731
6GF Score
MARX Biotech Co Ltd ROCO:7731
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MARX Biotech Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(85.926 + 243.589 + 34.948) - (102.507 + 0 + 41.996)
=219.96

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(66.649 + 110.456 + 28.654) - (123.984 + 0 + 40.307)
=41.468

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of MARX Biotech Co for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=209.272/( ( (221.99 + max(219.96, 0)) + (209.158 + max(41.468, 0)) )/ 2 )
=209.272/( ( 441.95 + 250.626 )/ 2 )
=209.272/346.288
=60.43 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 60.43% mean?
MARX Biotech Co (ROCO:7731) has a ROC (Joel Greenblatt) % of 60.43% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on MARX Biotech Co and its competitors. This is 398% above median its historical median of 12.14. According to the industry distribution chart, MARX Biotech Co ranks #253 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 37.8%.
Is MARX Biotech Co's ROC (Joel Greenblatt) % too high?
MARX Biotech Co's current ROC (Joel Greenblatt) % of 60.43% is 398% above median its 10-year median of 12.14. The Healthcare Providers & Services industry median ROC (Joel Greenblatt) % is 12.54. MARX Biotech Co's value of 60.43% is 381.9% above this industry median. Based on the distribution chart, MARX Biotech Co ranks #253 out of 669 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MARX Biotech Co has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does MARX Biotech Co's ROC (Joel Greenblatt) % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, MARX Biotech Co ranks #253 out of 669 companies for ROC (Joel Greenblatt) %. This puts MARX Biotech Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 12.54. MARX Biotech Co's value of 60.43% is 381.9% above this benchmark. While the company's 10-year median is 12.14 vs. the industry median of 12.54, MARX Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.54, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MARX Biotech Co's current ROC (Joel Greenblatt) % of 60.43% is 381.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on MARX Biotech Co and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MARX Biotech Co's current ROC (Joel Greenblatt) % is 60.43%, which is 398% above median its own 10-year median of 12.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MARX Biotech Co stock overvalued right now?
MARX Biotech Co (ROCO:7731) has a current ROC (Joel Greenblatt) % of 60.43%. The current ROC (Joel Greenblatt) % is 60.43%, which is 398% above median its 10-year median of 12.14 and 381.9% above the Healthcare Providers & Services industry median of 12.54. MARX Biotech Co's overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For MARX Biotech Co (ROCO:7731), the current ROC (Joel Greenblatt) % is 60.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MARX Biotech Co Business Description

Address 5th Floor, No. 655, Bannan Road, Zhonghe district, New Taipei, TWN
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
6GF Score

Get the complete analysis for ROCO:7731

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$4.70
Price